224 related articles for article (PubMed ID: 15739617)
21. SELECTIVE INHIBITION OF HEPATITIS C VIRUS REPLICATION BY ALPHA-ZAM, A
Oyero OG; Toyama M; Mitsuhiro N; Onifade AA; Hidaka A; Okamoto M; Baba M
Afr J Tradit Complement Altern Med; 2016; 13(6):144-148. PubMed ID: 28480371
[TBL] [Abstract][Full Text] [Related]
22. Modulation of host metabolism as a target of new antivirals.
Ikeda M; Kato N
Adv Drug Deliv Rev; 2007 Oct; 59(12):1277-89. PubMed ID: 17897752
[TBL] [Abstract][Full Text] [Related]
23. New antiviral pathway that mediates hepatitis C virus replicon interferon sensitivity through ADAR1.
Taylor DR; Puig M; Darnell ME; Mihalik K; Feinstone SM
J Virol; 2005 May; 79(10):6291-8. PubMed ID: 15858013
[TBL] [Abstract][Full Text] [Related]
24. Detection of anti-hepatitis C virus effects of interferon and ribavirin by a sensitive replicon system.
Kato T; Date T; Miyamoto M; Sugiyama M; Tanaka Y; Orito E; Ohno T; Sugihara K; Hasegawa I; Fujiwara K; Ito K; Ozasa A; Mizokami M; Wakita T
J Clin Microbiol; 2005 Nov; 43(11):5679-84. PubMed ID: 16272504
[TBL] [Abstract][Full Text] [Related]
25. Suppression of hepatitis C virus replication by cyclin-dependent kinase inhibitors.
Munakata T; Inada M; Tokunaga Y; Wakita T; Kohara M; Nomoto A
Antiviral Res; 2014 Aug; 108():79-87. PubMed ID: 24893207
[TBL] [Abstract][Full Text] [Related]
26. A Novel Small Molecule Inhibits Hepatitis C Virus Propagation in Cell Culture.
Oraby AK; Gardner CL; Needle RF; Kofahi HM; Everard KR; Taylor NGA; Rutihinda SG; Barry JP; Hirasawa K; Georghiou PE; Russell RS
Microbiol Spectr; 2021 Sep; 9(1):e0043921. PubMed ID: 34319169
[TBL] [Abstract][Full Text] [Related]
27. Screening for hepatitis C virus antiviral activity with a cell-based secreted alkaline phosphatase reporter replicon system.
Bourne N; Pyles RB; Yi M; Veselenak RL; Davis MM; Lemon SM
Antiviral Res; 2005 Aug; 67(2):76-82. PubMed ID: 15927278
[TBL] [Abstract][Full Text] [Related]
28. Development of a cell-based assay for high-throughput screening of inhibitors against HCV genotypes 1a and 1b in a single well.
Mondal R; Koev G; Pilot-Matias T; He Y; Ng T; Kati W; Molla A
Antiviral Res; 2009 Apr; 82(1):82-8. PubMed ID: 19174175
[TBL] [Abstract][Full Text] [Related]
29. Current status and future development of infectious cell-culture models for the major genotypes of hepatitis C virus: Essential tools in testing of antivirals and emerging vaccine strategies.
Ramirez S; Bukh J
Antiviral Res; 2018 Oct; 158():264-287. PubMed ID: 30059723
[TBL] [Abstract][Full Text] [Related]
30. Synthesis of New Indanyl Nucleoside Analogues and their Biological Evaluation on Hepatitis C Virus (HCV) Replicon.
Gómez ME; Gentile EA; Martini MF; Cuestas ML; Mathet VL; Moltrasio GY; Moglioni AG
Molecules; 2019 Mar; 24(5):. PubMed ID: 30862130
[TBL] [Abstract][Full Text] [Related]
31. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes.
Watashi K; Hijikata M; Hosaka M; Yamaji M; Shimotohno K
Hepatology; 2003 Nov; 38(5):1282-8. PubMed ID: 14578868
[TBL] [Abstract][Full Text] [Related]
32. Establishment of a subgenomic replicon for bovine viral diarrhea virus in Huh-7 cells and modulation of interferon-regulated factor 3-mediated antiviral response.
Horscroft N; Bellows D; Ansari I; Lai VC; Dempsey S; Liang D; Donis R; Zhong W; Hong Z
J Virol; 2005 Mar; 79(5):2788-96. PubMed ID: 15708997
[TBL] [Abstract][Full Text] [Related]
33. [Molecular virology of hepatitis C].
Moradpour D; Brass V; Gosert R; Wölk B; Blum HE
Praxis (Bern 1994); 2002 Dec; 91(51-52):2247-53. PubMed ID: 12564041
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and characterization of 1'-C-cyano-2'-fluoro-2'-C-methyl pyrimidine nucleosides as HCV polymerase inhibitors.
Kirschberg TA; Mish MR; Zhang L; Squires NH; Wang KY; Cho A; Feng JY; Fenaux M; Babusis D; Park Y; Ray AS; Kim CU
Bioorg Med Chem Lett; 2015 Mar; 25(5):1040-3. PubMed ID: 25650256
[TBL] [Abstract][Full Text] [Related]
35. Development and characterization of a replicon-based phenotypic assay for assessing HCV NS4B from clinical isolates.
Rajyaguru S; Yang H; Martin R; Miller MD; Mo H
Antiviral Res; 2013 Nov; 100(2):328-36. PubMed ID: 24013002
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and evaluation of optically pure dioxolanes as inhibitors of hepatitis C virus RNA replication.
Bera S; Malik L; Bhat B; Carroll SS; MacCoss M; Olsen DB; Tomassini JE; Eldrup AB
Bioorg Med Chem Lett; 2003 Dec; 13(24):4455-8. PubMed ID: 14643345
[TBL] [Abstract][Full Text] [Related]
37. Targeting cellular squalene synthase, an enzyme essential for cholesterol biosynthesis, is a potential antiviral strategy against hepatitis C virus.
Saito K; Shirasago Y; Suzuki T; Aizaki H; Hanada K; Wakita T; Nishijima M; Fukasawa M
J Virol; 2015 Feb; 89(4):2220-32. PubMed ID: 25473062
[TBL] [Abstract][Full Text] [Related]
38. Advances in hepatitis C: what is coming in the next 5 years?
Locarnini SA; Bartholomeusz A
J Gastroenterol Hepatol; 2002 Apr; 17(4):442-7. PubMed ID: 11982725
[TBL] [Abstract][Full Text] [Related]
39. The 2016 Lasker-DeBakey Clinical Medical Research Award: Innovative hepatitis C virus (HCV) replicons leading to drug development for hepatitis C cure.
Zhao Q; Xia N
Sci China Life Sci; 2016 Nov; 59(11):1198-1201. PubMed ID: 27785725
[No Abstract] [Full Text] [Related]
40. Hepatitis C virus virology and new treatment targets.
Meier V; Ramadori G
Expert Rev Anti Infect Ther; 2009 Apr; 7(3):329-50. PubMed ID: 19344246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
